FDA approves drugs from Gilead, Roche, TG Therapeutics to close 2022

The Food and Drug Administration’s main office for reviewing new medicines cleared 37 in 2022, closing out the year with approvals of treatments for HIV, lymphoma and multiple sclerosis.

The total was the lowest number since 2016, when the FDA’s Center for Drug Evaluation and Research granted 22 approvals, and was well below last year’s figure of 50. The center, known as CDER, approves most pharmaceutical treatments, as well as common biologic drugs like monoclonal antibodies.